Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BOSTON SCIENTIFIC CORPBSX · Entity 1897 | EVP & Pres, Interven Cardio | March 03, 2020 | March 05, 2020 |
| CVRx, Inc.CVRX · Entity 6920 | Director | June 01, 2026 | June 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BOSTON SCIENTIFIC CORP
Report date March 03, 2020 · Filed March 05, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 80,085 |
Last balance in matching sequence
After 2020-03-04 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2020-03-03 · Exercise / conversion · Acquired 3,303 · Balance 83,388 F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Row 2 · 2020-03-03 · Tax withholding · Disposed 1,507 · Balance 81,881 F2: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Row 3 · 2020-03-04 · Sale · Disposed 1,796 · Balance 80,085 F3: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. |
| Deferred Stock UnitsSEC Table II · derivative / convertible security · Expires 2022-03-03 | Direct | 6,606 |
Reported balance
After 2020-03-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-03-03 · Exercise / conversion · Disposed 3,303 · Balance 6,606 F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 3, 2018, the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F2: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.
F3: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.
F4: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 3, 2018, the first anniversary of the date of grant.
CVRx, Inc.
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,720 |
Reported balance
After 2026-06-01 transaction · row 1
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 8,720 · Balance 8,720 F1: Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.43 · Expires 2036-06-01 | Direct | 11,182 |
Reported balance
After 2026-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-01 · Grant · Acquired 11,182 · Balance 11,182 F1: Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Shockwave Medical, Inc.
Report date May 31, 2024 · Filed May 31, 2024
Section 16 reporting ended · disclosed 2024-05-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-05-31 transaction · row 1
1 source rowRow 1 · 2024-05-31 · Disposition to issuer · Disposed 1,733 · Balance 0 F1: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"), F2: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"),
F2: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration.
Silk Road Medical Inc
Report date September 17, 2024 · Filed September 18, 2024
Section 16 reporting ended · disclosed 2024-09-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-09-17 transaction · row 1
1 source rowRow 1 · 2024-09-17 · Disposition to issuer · Disposed 23,666 · Balance 0 F1: Of the reported shares, 5,859 are represented by restricted stock units, or RSUs, each of which represents a contingent right to receive one share of Issuer common stock. F2: Pursuant to the Agreement and Plan of Merger dated June 17, 2024, between the Issuer, Boston Scientific Corporation and Seminole Merger Sub, Inc, (the "Merger Agreement"), each share of Issuer common stock was canceled and converted into the right to receive $27.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding taxes. F3: Pursuant to the Merger Agreement, each RSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares underlying the RSUs, less applicable taxes and authorized deductions. |
Filing footnotes · ownership attribution and instrument terms
F1: Of the reported shares, 5,859 are represented by restricted stock units, or RSUs, each of which represents a contingent right to receive one share of Issuer common stock.
F2: Pursuant to the Agreement and Plan of Merger dated June 17, 2024, between the Issuer, Boston Scientific Corporation and Seminole Merger Sub, Inc, (the "Merger Agreement"), each share of Issuer common stock was canceled and converted into the right to receive $27.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding taxes.
F3: Pursuant to the Merger Agreement, each RSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares underlying the RSUs, less applicable taxes and authorized deductions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2026 Filed Jun 3, 2026 22:05 UTC | CVRx, Inc. CVRX · Entity 6920 | GrantStock Option (right to buy) · Derivative | 11,182 | $0.00 Strike: $5.43 | $0.00 |
DisclosureSEC source: 0001566080-26-000002 · form4-06032026_100659.xml · derivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,182 Underlying: Common Stock · 11,182 shares Expires 2036-06-01 F1 · derivative.exercise_date: Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 22:05 UTC | CVRx, Inc. CVRX · Entity 6920 | GrantCommon Stock | 8,720 | $0.00 | $0.00 |
DisclosureSEC source: 0001566080-26-000002 · form4-06032026_100659.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,720 F1 · shares: Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 21:13 UTC | CVRx, Inc. CVRX · Entity 6920 | GrantStock Option (right to buy) · Derivative | 19,554 | $0.00 Strike: $6.76 | $0.00 |
DisclosureSEC source: 0001415889-25-015807 · form4-06052025_090656.xml · derivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,554 Underlying: Common Stock · 19,554 shares Expires 2035-06-03 F1 · derivative.exercise_date: Vests on the earlier of June 3, 2026 or the Issuer's 2026 annual meeting of stockholders. Read SEC document |
| September 17, 2024 Filed Sep 18, 2024 20:48 UTC | Silk Road Medical Inc SILK · Entity 87417 | Disposition to issuerCommon Stock | 23,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-24-041421 · form4.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Of the reported shares, 5,859 are represented by restricted stock units, or RSUs, each of which represents a contingent right to receive one share of Issuer common stock. F2 · price: Pursuant to the Agreement and Plan of Merger dated June 17, 2024, between the Issuer, Boston Scientific Corporation and Seminole Merger Sub, Inc, (the "Merger Agreement"), each share of Issuer common stock was canceled and converted into the right to receive $27.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding taxes. F3 · price: Pursuant to the Merger Agreement, each RSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares underlying the RSUs, less applicable taxes and authorized deductions. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:44 UTC | CVRx, Inc. CVRX · Entity 6920 | GrantStock Option (right to buy) · Derivative | 36,136 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001415889-24-022938 · form4-09052024_080958.xml · derivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,136 Underlying: Common Stock · 36,136 shares Expires 2034-09-02 F1 · derivative.exercise_date: Vests as to one-third of the shares on each annual anniversary of the date of grant. Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 18:42 UTC | Silk Road Medical Inc SILK · Entity 87417 | GrantCommon Stock | 5,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-24-000882 · primary_01.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,666 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of SILK common stock. All of the RSUs vest on the earlier of (i) the one-year anniversary of the date the award is granted or (ii) the day prior to the date of the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| May 31, 2024 Filed May 31, 2024 20:28 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Disposition to issuerCommon Stock | 1,733 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001642545-24-000113 · wk-form4_1717187293.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"), F2 · price: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 06:01 UTC | Silk Road Medical Inc SILK · Entity 87417 | PurchaseCommon Stock | 11,700 | $16.99 | $198,783.00 |
DisclosureSEC source: 0001593968-24-000450 · primary_01.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,807 F1 · price: This transaction was executed in multiple trades at price ranging from $16.92 to $17.01. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 17:36 UTC | Silk Road Medical Inc SILK · Entity 87417 | GrantOption (right to buy) · Derivative | 3,566 | $0.00 Strike: $33.57 | $0.00 |
DisclosureSEC source: 0001593968-23-001036 · primary_01.xml · derivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,566 Underlying: Common Stock · 3,566 shares Expires 2033-06-21 F2 · shares: The shares subject to the options represent cash retainer that the Reporting Person elected to receive in the form of stock options. F3 · derivative.exercise_date: One fourth of the shares subject to the option shall vest on each of September 5, 2023, December 5, 2023, March 5, 2024, and the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 17:36 UTC | Silk Road Medical Inc SILK · Entity 87417 | GrantCommon Stock | 4,691 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-23-001036 · primary_01.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,107 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of SILK common stock. All of the RSUs vest on the earlier of (i) the one-year anniversary of the date the award is granted or (ii) the day prior to the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 22:47 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | GrantCommon Stock | 736 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-037552 · doc4.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,733 Read SEC document |
| May 16, 2023 Filed May 18, 2023 22:37 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | GrantCommon Stock | 997 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-030800 · doc4.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 997 F1 · shares: Reflects shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The shares subject to the restricted stock units vest in equal annual installments over three years commencing on May 16, 2023, subject to the Reporting Person's continued service through each relevant vesting date. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 18:20 UTC | Silk Road Medical Inc SILK · Entity 87417 | GrantOption (right to buy) · Derivative | 5,195 | $0.00 Strike: $36.90 | $0.00 |
DisclosureSEC source: 0001593968-22-001122 · primary_01.xml · derivative · entry 3 Ballinger Kevin J. · CIK 0001566080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,195 Underlying: Common Stock · 5,195 shares Expires 2032-06-09 F4 · derivative.exercise_date: All of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date the award is granted or (ii) the day prior to the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 18:20 UTC | Silk Road Medical Inc SILK · Entity 87417 | GrantOption (right to buy) · Derivative | 3,214 | $0.00 Strike: $36.90 | $0.00 |
DisclosureSEC source: 0001593968-22-001122 · primary_01.xml · derivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,214 Underlying: Common Stock · 3,214 shares Expires 2032-06-09 F2 · shares: The shares subject to the options represent cash retainer that the Reporting Person elected to receive in the form of stock options. F3 · derivative.exercise_date: One fourth of the shares subject to the option shall vest on each of September 5, 2022, December 5, 2022, March 5, 2023, and the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 18:20 UTC | Silk Road Medical Inc SILK · Entity 87417 | GrantCommon Stock | 846 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-22-001122 · primary_01.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,416 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of SILK common stock. All of the RSUs vest on the earlier of (i) the one-year anniversary of the date the award is granted or (ii) the day prior to the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 18:33 UTC | Silk Road Medical Inc SILK · Entity 87417 | GrantOption (right to buy) · Derivative | 4,066 | $0.00 Strike: $50.40 | $0.00 |
DisclosureSEC source: 0001593968-21-001667 · primary_01.xml · derivative · entry 3 Ballinger Kevin J. · CIK 0001566080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,066 Underlying: Common Stock · 4,066 shares Expires 2031-06-17 F4 · derivative.exercise_date: All of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date the award is granted or (ii) the day prior to the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 18:33 UTC | Silk Road Medical Inc SILK · Entity 87417 | GrantOption (right to buy) · Derivative | 2,546 | $0.00 Strike: $50.40 | $0.00 |
DisclosureSEC source: 0001593968-21-001667 · primary_01.xml · derivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,546 Underlying: Common Stock · 2,546 shares Expires 2031-06-17 F2 · shares: The shares subject to the options represent cash retainer that the Reporting Person elected to receive in the form of stock options. F3 · derivative.exercise_date: One fourth of the shares subject to the option shall vest on each of September 5, 2021, December 5, 2021, March 5, 2022, and the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 18:33 UTC | Silk Road Medical Inc SILK · Entity 87417 | GrantCommon Stock | 570 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-21-001667 · primary_01.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 570 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of SILK common stock. All of the RSUs vest on the earlier of (i) the one-year anniversary of the date the award is granted or (ii) the day prior to the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 19:14 UTC | Silk Road Medical Inc SILK · Entity 87417 | GrantOption (right to buy) · Derivative | 1,023 | $0.00 Strike: $60.69 | $0.00 |
DisclosureSEC source: 0001593968-21-000083 · primary_01.xml · derivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,023 Underlying: Common Stock · 1,023 shares Expires 2031-01-05 F1 · shares: The shares subject to the options represent cash retainer that the Reporting Person elected to receive in the form of stock options. F2 · derivative.exercise_date: One third of the shares subject to the option shall vest on each of December 5, 2020, March 5, 2021, and the date of the Issuer's 2021 annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| December 03, 2020 Filed Dec 4, 2020 17:50 UTC | Silk Road Medical Inc SILK · Entity 87417 | GrantOption (right to buy) · Derivative | 6,723 | $0.00 Strike: $56.13 | $0.00 |
DisclosureSEC source: 0001593968-20-002330 · primary_01.xml · derivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,723 Underlying: Common Stock · 6,723 shares Expires 2030-12-03 F1 · derivative.exercise_date: One third of the shares subject to the option shall vest on December 3, 2021 and each one-year anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| March 04, 2020 Filed Mar 5, 2020 21:10 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 1,796 | $38.05 | $68,337.80 |
DisclosureSEC source: 0001225208-20-004422 · doc4.xml · nonDerivative · entry 3 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,085 F3 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 21:10 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 3,303 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-004422 · doc4.xml · derivative · entry 4 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,606 Underlying: Common Stock · 3,303 shares Expires 2022-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 3, 2018, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 3, 2018, the first anniversary of the date of grant. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 21:10 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,507 | $37.23 | $56,105.61 |
DisclosureSEC source: 0001225208-20-004422 · doc4.xml · nonDerivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,881 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 21:10 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 3,303 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-004422 · doc4.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,388 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 21:09 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 15,783 | $37.21 | $587,220.72 |
DisclosureSEC source: 0001225208-20-004146 · doc4.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,085 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $36.90 to $37.61, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:24 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 5,658 | $41.15 | $232,826.70 |
DisclosureSEC source: 0001225208-20-003559 · doc4.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,868 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:24 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantPerformance Share Units · Derivative | 10,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003559 · doc4.xml · derivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,666 Underlying: Common Stock · 10,666 shares Expires 2021-12-31 F3 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · shares: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2021. F4 · derivative.exercise_date: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2021. F4 · derivative.expiration_date: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2021. F4 · balance_after: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2021. Read SEC document |
| February 23, 2020 Filed Feb 24, 2020 22:07 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 3,679 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003281 · doc4.xml · derivative · entry 9 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,679 shares Expires 2020-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. Read SEC document |
| February 23, 2020 Filed Feb 24, 2020 22:07 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,678 | $42.62 | $71,516.36 |
DisclosureSEC source: 0001225208-20-003281 · doc4.xml · nonDerivative · entry 6 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,526 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 23, 2020 Filed Feb 24, 2020 22:07 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 3,679 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003281 · doc4.xml · nonDerivative · entry 5 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,204 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 22, 2020 Filed Feb 24, 2020 22:07 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 3,766 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003281 · doc4.xml · derivative · entry 8 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,766 Underlying: Common Stock · 3,766 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| February 22, 2020 Filed Feb 24, 2020 22:07 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,718 | $42.62 | $73,221.16 |
DisclosureSEC source: 0001225208-20-003281 · doc4.xml · nonDerivative · entry 4 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,525 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 22, 2020 Filed Feb 24, 2020 22:07 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 3,766 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003281 · doc4.xml · nonDerivative · entry 3 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,243 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:07 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,959 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003281 · doc4.xml · derivative · entry 7 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,880 Underlying: Common Stock · 2,959 shares Expires 2023-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:07 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,350 | $42.62 | $57,537.00 |
DisclosureSEC source: 0001225208-20-003281 · doc4.xml · nonDerivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,477 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:07 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,959 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003281 · doc4.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,827 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 19, 2020 Filed Feb 19, 2020 22:28 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 1,757 | $42.31 | $74,338.67 |
DisclosureSEC source: 0001225208-20-002830 · doc4.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,868 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:28 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 46,460 | $0.00 Strike: $42.16 | $0.00 |
DisclosureSEC source: 0001225208-20-002830 · doc4.xml · derivative · entry 3 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,460 Underlying: Common Stock · 46,460 shares Expires 2030-02-18 F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:28 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantDeferred Stock Units · Derivative | 12,452 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002830 · doc4.xml · derivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,452 Underlying: Common Stock · 12,452 shares Expires 2024-02-18 F3 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:07 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 3,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002600 · doc4.xml · derivative · entry 5 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,690 Underlying: Common Stock · 3,230 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:07 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,473 | $42.31 | $62,322.63 |
DisclosureSEC source: 0001225208-20-002600 · doc4.xml · nonDerivative · entry 4 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,625 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:07 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 3,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002600 · doc4.xml · nonDerivative · entry 3 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,098 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 21:07 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 11,463 | $42.31 | $484,999.53 |
DisclosureSEC source: 0001225208-20-002600 · doc4.xml · nonDerivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,868 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 21:07 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 27,246 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002600 · doc4.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,331 F1 · shares: On March 3, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2019 and subject to the completion of the concurrent three-year individual service period. On February 14, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| January 03, 2020 Filed Jan 6, 2020 21:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 11,036 | $44.52 | $491,322.72 |
DisclosureSEC source: 0001225208-20-000514 · doc4.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,057 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionPerformance Share Units · Derivative | 16,117 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-000289 · doc4.xml · derivative · entry 3 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,117 shares Expires 2019-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · shares: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The Performance Share Units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2019. F1 · derivative.exercise_date: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The Performance Share Units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2019. F1 · derivative.expiration_date: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The Performance Share Units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2019. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 5,081 | $45.22 | $229,762.82 |
DisclosureSEC source: 0001225208-20-000289 · doc4.xml · nonDerivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,093 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 16,117 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-000289 · doc4.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,174 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The Performance Share Units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2019. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| March 03, 2019 Filed Mar 4, 2019 21:29 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 3,302 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004340 · doc4.xml · derivative · entry 4 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,909 Underlying: Common Stock · 3,302 shares Expires 2022-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 3, 2018, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 3, 2018, the first anniversary of the date of grant. Read SEC document |
| March 03, 2019 Filed Mar 4, 2019 21:29 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,506 | $40.75 | $61,369.50 |
DisclosureSEC source: 0001225208-19-004340 · doc4.xml · nonDerivative · entry 3 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,368 F3 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.